2026-11-14 · 2026-11 / week-2
Cerenome's first diagnostic revenue leaves the cash and listing gap open
Cerenome's first diagnostic revenue leaves the cash and listing gap open
Summary: Cerenome recorded its first CNSide diagnostic revenue in Q3 and reported an initial commercial payer payment in October. The same Nov. 13 filing shows $4.9 million of cash, equivalents and investments at quarter-end, $21.0 million of nine-month operating cash use, substantial doubt about going concern, and an expected Nasdaq financial-standard deficiency letter. It also faces a separate below-$1 bid-price risk. CNSY closed at $0.9502 after rising 23.32% on 8.13 million shares. The new revenue is real progress, but it does not establish collections, runway, a stable share count or a price that clears the long hurdle. Reject / no trade.
Opportunity Ranking
This ranks information value and falsifiability, not executable opportunities. The broad-market control was SPY at $754.37, down 0.36% on Nov. 13; it does not provide an issuer-specific catalyst.
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerenome (CNSY) | Long | First recognized diagnostic revenue and expanded coverage versus cash burn, financing claims and listing pressure | Nov. 13 10-Q, release and regular close | Nov. 16 call; later collections and compliance updates | 8.13M shares traded, but current holders, short interest and borrow are unverified | Reject: 0% base marker, -40.0% downside marker, 0:1 base/adverse | Thin issuer with a one-day volume surge; spread, depth and exit capacity are unknown | Going-concern disclosure, dilution and Nasdaq risk |
| 2 | Figure Technology Solutions (FIGR) | Long | 135% marketplace-volume growth and 84% revenue growth versus a 90-basis-point fall in net take rate | Nov. 12 Q3 release; Nov. 13 close | Next reported loan yield, Kiavi integration and credit performance | 3.83M shares traded; direct ownership and dealer positioning not checked | Reject: no sourced +10% base with a -5% adverse bound | More active tape, but market structure was not verified | Growth includes acquired volume; unit yield fell |
| 3 | TOMI Environmental (TOMZ) | Long | Preliminary return to operating profit versus a small revenue base and unresolved convertible-note accounting | Nov. 12 preliminary release; Nov. 13 close | Filed Q3 statements and order conversion | 92,512 shares traded; current positioning unknown | Reject: upside and downside are not bounded | Low observed volume; spread, depth and exit capacity are unknown | Preliminary numbers may change; backlog is not revenue |
Selected opportunity: CNSY as the most decision-relevant no-trade screen, not as the best executable long.
Why this one now: The new filing answers the question left open by the September screen: whether CNSide had begun to recognize commercial revenue. It had. The same filing also supplies a fresh cash, share-count, redemption and Nasdaq-compliance picture. Those facts sharpen the gap between marketable payer coverage and equity actually supported by collections.
What should surprise the reader: The issuer says its contracted payer footprint is about 190 million covered lives. Q3 included 222 tests billed at list prices, $1.55 million of gross billings and $0.722 million of recognized net diagnostic revenue. Covered lives, list-price billings, recognized revenue and cash collected are four different measures.
Why CNSY Ranks First for Research, Not as a Trade
Cerenome's September 14 article, “Cerenome buys runway with a secured convertible, but the royalty and share-count bridge still breaks the long,” treated diagnostic revenue and reimbursement as unproven. This article uses materially new evidence: Q3 recognized revenue, an October payer payment, Nov. 13 cash and share disclosures, post-quarter ATM sales, note redemptions and a disclosed Nasdaq deficiency risk. The conclusion remains no trade, but the evidence boundary has changed.
The prior article's $1.00 bottom marker was crossed when CNSY closed at $0.57 on Nov. 9. Its horizon was tied to financing and operating milestones rather than a fixed terminal date. This is an interim path observation, not a matured forecast, position return or calibrated miss.
Why It Could Move More Than 5% Soon
As noted above, the latest session showed an unusually large price and volume response. The Nov. 16 call is a dated catalyst for commercial and clinical updates. Another move above 5% is plausible in either direction; the recent jump is evidence of volatility, not evidence of favorable expected return.
TOMZ also moved 10.43% on Nov. 13, but traded 92,512 shares. FIGR's results produced a 6.12% Nov. 12 rise followed by a 1.75% decline on Nov. 13. These price reactions do not establish that any candidate has bounded downside.
10/5 Asymmetry Gate
The reference-only map below gives CNSY a 0% base move and a 40.0% adverse move. Base-to-adverse reward/risk is 0:1. The positive top case is not the highest-probability case. The Desk requires a base case of at least +10%, credible adverse risk no worse than -5%, at least 2:1 gross reward/risk and favorable expected value after costs from a verified executable entry. CNSY meets none of those tests.
Status: Reject / no trade. The map is anchored to recent prices, not fair value. Entry is null; execution is disabled.
The Setup
Fact: In Q3, CNSide Diagnostics billed 222 tests. Cerenome reported $1.55 million in gross billings at list prices and $0.722 million of net diagnostic revenue after estimated payer adjustments and price concessions (10-Q). It said it received an initial commercial payer payment in October, but the filing does not give the amount, paid-claim ratio, payer yield or time to payment.
Fact: Aetna coverage effective Nov. 1 is the company's first national agreement covering both tumor-cell enumeration and molecular profiling. Cerenome says its total contracted footprint is about 190 million covered lives (Q3 release). This is an issuer-reported coverage measure, not a count of patients, ordered tests or paying claims.
Fact: Q3 operating loss was $7.5 million and net loss was $8.657 million. Nine-month operating cash use was $21.0 million. At Sept. 30, cash, cash equivalents and investments totaled $4.9 million, down from $8.6 million at June 30 (10-Q). Of the Sept. 30 total, the 10-Q lists $0.879 million of cash and $3.992 million of investments.
Inference: Coverage and actual billed testing have advanced, but this first quarter of recognized revenue is far below the quarterly operating loss. The next underwriting question is collection and unit economics, not the size of the payer footprint.
The Market Price
StockAnalysis, citing S&P Global Market Intelligence, reports a Nov. 13 regular-session close of $0.9502, up $0.1797 or 23.32%, with a $0.81-$1.18 range and 8,134,058 shares traded. The previous close was $0.77. This is the latest completed regular-session observation as of publication on Saturday, Nov. 14, Singapore time. The after-hours quote is not used.
At $0.9502, the share price is about 66.7% above the Nov. 9 close of $0.57. CNSY remained below $1.00 at the Nov. 13 regular close. No reliable current market-cap figure is used: the latest dated share count and later ATM sales overlap, and the exact Nov. 13 denominator is not disclosed.
The Mispricing
A bullish interpretation is that the first recognized revenue, October payment, expanded Aetna coverage and new molecular test menu reduce commercial risk. The 23.32% rise is consistent with a sharp repricing after the results, but price action alone cannot reveal the market's prior assumptions.
The price action supports a sharp change in sentiment, but not a valuation conclusion. The disagreement is between commercial access and the still-unproven conversion from tests to cash, against material financing and listing constraints. No current consensus estimate or market-implied revenue path was verified. Unknown: I do not have sufficient reliable data to quantify fair value from the current share price.
The Positioning
Observed: CNSY's Friday volume was about 25.5 times Thursday's volume as the share price rose. That supports an event-driven trading-activity description.
Unknown: Current beneficial ownership, short interest, borrow, options, dealer exposure, institutional flows, spread, depth, venue quality, volume quality and exit capacity were not verified. The volume spike does not prove a short squeeze or durable accumulation. Positioning score is 2/5.
The Catalyst
| Event | Timing | Test |
|---|---|---|
| Q3 business update call | Monday, Nov. 16, 8:30 a.m. ET | Ask for cash actually collected, paid claims, net reimbursement per test, test volume, the current share count and the status of Nasdaq notices. |
| Nasdaq continued-listing process | The 10-Q says the company expects a deficiency letter; timing after filing is not verified | Confirm whether a notice arrived, which standard is deficient, and any cure plan or hearing outcome. Do not infer that a notice has already been issued. |
| Next quarterly filing | Exact date not verified | Reconcile collections, receivables, operating cash use, note balance, ATM shares and the post-period denominator. |
| ReSPECT-GBM topline | Issuer expects mid-2027 | Review efficacy and safety data separately from the CNSide commercial thesis. |
The 10-Q says the closing bid had been below $1.00 since Nov. 4 and that Cerenome had not received a bid-price deficiency notice since May 2025. It also says that, because of a prior reverse split within the one-year period, the company may not receive another ordinary bid-price compliance window if it falls below $1.00; a delisting determination may follow. Separately, it expects a deficiency letter because stockholders' equity is below $2.5 million and market value of listed securities has been below $35 million for 30 consecutive business days. The filing says a company may have 45 calendar days after such notice to submit a compliance plan. These are disclosed risks and expected steps, not proof that Nasdaq has issued a new notice or ordered delisting.
The Payoff
Cerenome's strongest long path is that payer contracts convert into repeat testing and cash faster than financing claims and operating costs consume capital. The stress path is not a normal valuation reset: slower collections, continued losses, additional issuance or a listing disruption could impair the common equity sharply. The company has also said the first ten patients in a ReSPECT-LM repeat-dose cohort had no dose-limiting toxicities or treatment discontinuations due to adverse events. That is an issuer-reported early safety observation, not efficacy evidence.
A defensible intrinsic valuation cannot be built from the data reviewed. The map uses only observable price markers to show why this is not a bounded long.
Price Target and Probability Map
Reference-only, 20-session path through Dec. 14, 2026. These are observed price markers, not fair-value targets or floors. Probabilities are subjective analyst judgments, not observed frequencies.
| Scenario | Probability | Target / Level | Return / Payoff | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 15% | $1.18 | +24.2% | Through Dec. 14, 2026 | Retest of Nov. 13 intraday high after a favorable commercial update | Low |
| Base Case | 55% | $0.9502 | 0.0% | Same | Price stays near the last close while collections and compliance remain unresolved | Low |
| Bottom Case | 30% | $0.57 | -40.0% | Same | Reversion to the Nov. 9 close as financing or listing risk dominates | Low |
| Invalidation | n/a | New cash, collection, share-count or compliance evidence changes the underwriting | No position exists to invalidate | Before any future reconsideration | Rebuild the thesis; this Reject record is not an open trade | Medium |
Probability-weighted expected price: $0.8706, or -8.4% gross before costs. This is a price-path calculation, not enterprise value. Costs and exit slippage are unquantified.
Current market level and timestamp: $0.9502, Nov. 13, 2026, 4:00 p.m. EST regular-session close.
Primary instrument: CNSY common stock. No leveraged expression is supported.
10/5 favorable base move: 0.0% from the reference close.
10/5 credible adverse move: -40.0% to a recent closing marker; losses beyond this level, including a total loss, remain possible.
10/5 measurement basis: Reference-only. No verified executable entry.
10/5 status: Reject / no trade.
Confidence: Low. The path markers are public prices, but scenario probabilities and the 20-session horizon are analyst judgments.
The Kill Shot
The strongest counterargument is that first recognized revenue is more meaningful than a press-release pipeline: Aetna coverage is effective, the company reports an October payment, and it has expanded the test menu. The issuer also says it raised approximately $3.8 million net through the ATM after quarter-end.
That case still leaves the common shareholder behind a cash and claim problem. The $3.8 million ATM total covers Oct. 1-Nov. 12. The 10-Q says the investor may require approximately $1.6 million of note redemption from ATM proceeds at 105% of the conversion amount; Cerenome paid $0.4 million in October, reducing principal from $3.2 million to $2.9 million. The filing separately reports 9,776,935 common shares outstanding on Nov. 9 and 1,934,812 ATM shares issued across Oct. 1-Nov. 12. Those periods overlap, so the figures must not be added. The exact share count at the Nov. 13 close is unknown.
Load-bearing assumption: CNSide must turn coverage into repeat paid claims and cash before financing costs, dilution and operating losses overwhelm common equity. The current filing does not show that conversion.
What Could Go Wrong
The two largest downside paths are that paid collections fail to catch up with operating costs, and that financing or listing pressure further weakens the common-equity claim. A trial safety update can also be mistaken for efficacy. The detailed exposures are in the Risk Audit below; each can produce a loss larger than the $0.57 marker.
What Would Prove This Wrong
A later filing showing repeated paid tests, disclosed net reimbursement and collection timing, falling operating cash use, a reconciled post-ATM share count and a credible Nasdaq cure would weaken the rejection. A coverage expansion or gross list-price billing figure alone would not.
The cheapest next test is the Nov. 16 call: record cash received, paid claims, tests by payer, net revenue per test, note redemptions, shares outstanding and the exact compliance-notice status. If management does not disclose these, keep them unknown.
Risk Audit
- Capital: $4.9 million of cash and investments at quarter-end versus $21.0 million of nine-month operating cash use; post-quarter proceeds and redemptions do not yet produce a current cash runway.
- Claims: $1.55 million of list-price billings is not revenue or cash. Recognized net revenue was $0.722 million; actual collection yield remains unknown.
- Common-equity claims: The note is secured, convertible and tied to a 2.5% CNSide gross-revenue royalty. The $20 million facility headline does not mean all tranches were funded.
- Denominator: The Nov. 9 share count and Oct. 1-Nov. 12 ATM issuance overlap. No exact close-date denominator or fully diluted share count is available.
- Listing: The company expects a financial-standard deficiency letter and reports a bid-price risk after its recent reverse split. A delisting path could impair liquidity, but no new notice was confirmed in this review.
- Market: Friday's volume surge is not exit-liquidity proof. Gaps, halts, slippage and trading pauses can worsen losses.
- Clinical: Patient tolerability is not efficacy, and the key GBM update is expected in 2027.
Best Trade Strategy
No trade. Keep entry.price null and execution.can_execute false. Do not treat the $0.9502 close, the $0.57 marker or the Nov. 16 call as an order trigger. Reconsider only after a filed cash-and-share bridge, real collection evidence, a verified Nasdaq status and fresh market-structure data. No options, leverage, margin, market orders or price-floor assumptions.
Sources
- Cerenome Q3 2026 Form 10-Q, filed Nov. 13, 2026.
- Cerenome Q3 results and business update, Nov. 13, 2026.
- CNSY price history, S&P Global Market Intelligence close and volume through Nov. 13, 2026.
- Figure Technology Solutions Q3 2026 results, Nov. 12, 2026.
- FIGR price history, Nov. 12-13, 2026.
- TOMI preliminary Q3 2026 results, issuer release, Nov. 12, 2026.
- TOMZ price history, Nov. 12-13, 2026.
- SPY price history, Nov. 13, 2026.
Research Quality Scorecard
| Criterion | Score | Evidence |
|---|---|---|
| Market disagreement | 5/5 | New revenue and payer access conflict with cash, financing and listing evidence |
| Evidence base | 5/5 | Fresh filed Q3 report, issuer release and dated close |
| Positioning and flows | 2/5 | One-day activity is observed; ownership, short and options data are unknown |
| Catalyst path | 4/5 | Nov. 16 update is dated; collections and compliance tests are observable |
| Payoff architecture | 2/5 | Market markers show asymmetry, but no defensible fair value or downside floor |
| Invalidation discipline | 4/5 | Cash, collections, denominator and Nasdaq status have clear tests |
| Differentiated insight | 4/5 | Separates covered lives, billed value, revenue and cash while updating the old thesis |
| Client value | 4/5 | Gives a useful no-trade map and a specific next evidence request |
Total: 30/40. This is a short no-trade screen. The failed 10/5 economics force Reject regardless of score.
Bottom Line
Cerenome has crossed from planned CNSide commercialization to recognized diagnostic revenue. That matters. It has not yet crossed from payer coverage to repeatable cash. The Nov. 13 filing adds a $21 million nine-month operating cash use, explicit going-concern doubt, fresh ATM issuance, note-redemption claims and an expected Nasdaq financial-standard deficiency letter. It also faces a separate below-$1 bid-price risk. The $0.9502 close and one-day rally do not establish a favorable, bounded long. Reject / no trade.
AI Illustration Prompt
Editorial financial illustration: a small CNS diagnostic lab reports a single recognized revenue receipt while a cash runway gauge falls beside a secured convertible note and a share ledger marked “ATM THROUGH NOV. 12”; a Nasdaq compliance letter sits unopened beside a calendar marked “NOV. 16 UPDATE”; use muted clinical teal, graphite, cream and a restrained red accent; no stock chart, no price prediction, no logos; documentary institutional magazine style with generous negative space; add a subtle readable “The Mispricing Desk” watermark in the lower-right corner.